Work overview

Section 17 of 18

Clinical trial number

NF-κB across the Alzheimer disease spectrum: Context-dependent protective and pathogenic roles

Ali Azargoonjahromi, Fatemeh Abutalebian, and Hamide Nasiri · 2026

Contents

Section 17 of 18

  1. 01Introduction
  2. 02Literature Identification and Appraisal of Evidence
  3. 03Human Evidence for Context-Dependent NF-κB Dysregulation in AD
  4. 04Neuronal NF-κB Signaling: From Adaptive Stress Responses to Pathological Signaling
  5. 05Microglial NF-κB Signaling: Distinguishing Amyloid Clearance, Inflammation, and Tau Propagation
  6. 06Astrocytic NF-κB Signaling: Compensatory Functions and Neurotoxic Reactivity
  7. 07Neurovascular NF-κB Signaling: Blood–Brain Barrier (BBB) Dysfunction, Hypoperfusion, and Impaired Aβ Efflux
  8. 08IKKβ in AD: Distinguishing Kinase Functions from NF-κB-Dependent Transcription
  9. 09Knowledge Gaps and Priorities for Future Research
  10. 10Conclusion
  11. 11Abbreviations
  12. 12Ethical Approval and Consent to Participate
  13. 13Funding
  14. 14CRediT authorship contribution statement
  15. 15Authors’ Contributions
  16. 16Consent for Publication
  17. 17Clinical trial number
  18. 18Declaration of Competing Interest
Text size
Work overview

Section 17 of 18

Clinical trial number

Ali Azargoonjahromi, Fatemeh Abutalebian, and Hamide Nasiri · about 1 minutes

Original source ↗

Not applicable.